Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01696500
Other study ID # NPB-01-07/C-01
Secondary ID
Status Completed
Phase Phase 3
First received September 20, 2012
Last updated July 1, 2014
Start date October 2012
Est. completion date June 2014

Study information

Verified date October 2013
Source Nihon Pharmaceutical Co., Ltd
Contact n/a
Is FDA regulated No
Health authority Japan: Pharmaceuticals and Medical Devices Agency
Study type Interventional

Clinical Trial Summary

Patients diagnosed with Stevens-Johnson syndrome and Toxic Epidermal Necrolysis were confirmed based on the investigators national diagnostic criteria. Patients who meet all inclusion criteria and do not conflict with the exclusion criteria will receive NPB-01 (intravenous immunoglobulin) 400mg/kg/day for five consecutive days. Subsequently, efficacy of NPB-01 for therapy of Stevens-Johnson syndrome and Toxic Epidermal Necrolysis will be evaluated the disease evaluation score et al.

As a safety endpoint, the safety of NPB-01 will be investigated the occurrence of adverse events by 20 days after the start of the study treatment.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date June 2014
Est. primary completion date June 2014
Accepts healthy volunteers No
Gender Both
Age group 20 Years and older
Eligibility Inclusion Criteria:

1. Patients who the disease evaluation score is more than 14 at study medication received.

2. Patients with corticosteroids over 20mg/day(Prednisolone) at study medication received and continued this treatment more than 2 days.

3. Patients with treatment effect is insufficiency before study medication received and need additional treatment.

4. Patients aged more than twenty years old at informed consent.

Exclusion Criteria:

1. Patients who the SCORTEN score is more than 4 at study medication received.

2. Patients with multiple organ failure at study medication received.

3. Patients with severe respiratory disorder at study medication received.

4. Patients with Drug-induced hypersensitivity syndrome (DIHS) at informed consent.

5. Patients with malignancy during treatment at informed consent.

6. Patients treated with corticosteroids dosage is change at 2 days before study medication received.

7. Patients treated with corticosteroids pulse therapy(including semi-pulse therapy) at 2 days before study medication received.

8. Patients treated with plasmapheresis at 2 days before study medication received.

9. Patients treated with high-dose intravenous immunoglobulin at 28 days before informed consent.

10. Patients with history of shock or hypersensitivity for NPB-01.

11. Patients with IgA deficiency.

12. Patients with severe impaired liver function diagnosed virus hepatitis or cirrhosis et al.

13. Patients with more than 2mg/dL serum creatinine.

14. Patients with severe cerebro- or cardiovascular disorders.

15. Patients with high risk of thromboembolism.

16. Patients with hemolytic/hemorrhagic anemia.

17. Patients with severe decreased cardiac function.

18. Patients with decreased platelet less than 75,000/µL..

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Intravenous immunoglobulin


Locations

Country Name City State
Japan Nihon Pharmaceutical Co., Ltd Tokyo

Sponsors (1)

Lead Sponsor Collaborator
Nihon Pharmaceutical Co., Ltd

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary disease evaluation score 7 days No
Secondary disease evaluation score 4 ,10 ,20 days No
Secondary avulsed skin area 20 days No
Secondary erythematous area 20 days No
See also
  Status Clinical Trial Phase
Recruiting NCT03659227 - Drug Reactions Sampling (COLLECTIONTOXIDERMIES)
Terminated NCT02037347 - Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis Phase 1/Phase 2
Withdrawn NCT02126020 - Topical Infliximab in Autoimmune Eyes With Keratoprosthesis Phase 1/Phase 2
Active, not recruiting NCT05520086 - Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis. Phase 1/Phase 2
Completed NCT06263140 - Vitamin D Levels in Non-immediate Drug Hypersensitivity Case-control Study
Available NCT02149732 - Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation Phase 1/Phase 2
Recruiting NCT05284929 - Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population
Recruiting NCT02987257 - NATIENS: Optimal Management and Mechanisms of SJS/TEN Phase 3
Completed NCT02945176 - Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation N/A
Not yet recruiting NCT03585946 - Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis
Recruiting NCT04313725 - Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease N/A
Recruiting NCT03046914 - HLA-B*5801 Screening to Prevent Allopurinol-induced Severe Cutaneous Adverse Reaction N/A
Completed NCT01488396 - Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye Phase 4
Withdrawn NCT01256489 - Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS) Phase 1/Phase 2
Active, not recruiting NCT01122303 - Corneal Epitheliotropic Factors in Autologous Serum Eye Drops in Nonautoimmune and Stevens-Johnson Syndrome With Dry Eye N/A
Recruiting NCT05145959 - Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis N/A
Completed NCT00844038 - Stevens-Johnson Syndrome Antimicrobial N/A